Study Linking Z-Pak to Increased Death Risk Being Reviewed by FDA

Study Linking Z-Pak to Increased Death Risk Being Reviewed by FDA

Study Linking Z-Pak to Increased Death Risk Being Reviewed by FDA

The U.S. Food & Drug Administration (FDA) is reviewing a new study that reported an increased risk of sudden, heart-related deaths among people using the antibiotic Zithromax (azithromycin), known popularly as Z-Pak. In a statement issued late yesterday, the FDA said patients being treated with Zithromax should not stop taking the antibiotic without speaking with their doctor. The agency also advised physicians to be aware that Zithromax and other antibiotics in the same class, called macrolide, have the potential to cause potentially deadly heart arrhythmias.

© 2005-2017 Parker Waichman LLP ®. All Rights Reserved.